Senses Disorder TRIZ Cases

Formulations using ethyl esters and free fatty acids overcome poor in vivo conversion rates, improving omega-3 absorption via self-nanoemulsifying systems.

A segmented tablet design pairs an immediate-release DPP-4 inhibitor layer with an extended-release metformin core to maintain chemical stability.

Hydrocolloid prevents phase separation in mometasone and olopatadine nasal suspension, maintaining dose uniformity.

Justicia procumbens extract inhibits IgE antibody secretion and mast cell degranulation to address side effects from conventional treatments.

Dynamic viscosity changes resolve the trade-off between easy administration and prolonged drug retention.

Infusing cultured functional human corneal endothelial cells regenerates the anterior chamber lining, avoiding donor shortages and irregular astigmatism.

Engineered human antibodies selectively bind VEGFR2 to inhibit angiogenesis while preserving VEGFR1 function, reducing bone metabolism adverse effects.

A Wittig reaction process using potassium tert-butoxide and stoichiometric reagents produces Olopatadine intermediates with high Z/E isomer selectivity.

Adding trometamol to eye drops stabilizes thermally unstable medicaments, preventing thermal hydrolysis and enabling storage at elevated temperatures.

Modifying substituents on pyrazole or pyridine rings enhances RBP4-lowering activity to treat age-related macular degeneration.

A synergistic herbal composition of Foeniculum vulgare, Murraya koenigii, and Triphala extracts formulated as ophthalmic drops.

A chimeric cytokine domain combines segments from IL-1β and IL-1Ra to bind the IL-1 receptor type I with high affinity.

Pure (+)-azasetron enantiomer composition enhances bioavailability in the inner ear.

Germline framework replacement enhances binding affinity while reducing immunogenicity risks associated with murine sequences.

A synergistic oral composition combines lutein ester microcapsules with sodium hyaluronate to protect ocular tissues.

Segmented naphthyridine structures target distinct Akt isoforms, bypassing non-specific effects of prior kinase inhibitors.

A lipopeptide composition promotes collagen production and activates cells to improve skin elasticity.

A hyaluronan-binding peptide linked to an optically detectable moiety renders the vitreous cavity visible during surgery.

Inorganic phosphate salts induce antibody crystallization at pH 3 to 5, enabling industrial scale production without toxic agents.

Topical botulinum toxin penetrates lipid membranes for sustained treatment, eliminating needle injection discomfort and reducing dosing frequency.

Engineered commensal bacteria reprogram intestinal cells to secrete insulin, reducing exogenous therapy needs and side effects.

SH-11037 reduces lesion volumes and maintains retinal function while avoiding systemic side effects associated with biologic anti-VEGF therapies.

A gene therapy expression system uses miRNA target sequences to regulate FKRP protein levels in skeletal muscle tissue.

Dendrobium nobile Lindley downregulates VEGF and HIF-1α to resolve retinal ischemia in developmental vascular disorders.

A solid fibrous carrier dissolves in tears to release active agents, improving corneal penetration and reducing side effects from rapid clearance.

Topical aptamer-conjugated nanoparticles detect VEGF levels and inhibit ocular angiogenesis, eliminating repeated intraocular injections.

A nutritional composition combines unsaturated fatty acids and nitric oxide releasing compounds to support visual system health.

Amorphous solid dispersion enhances bioavailability of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide.

Small molecule inhibitors disrupt electrostatic interactions between βL-crystallin proteins to prevent aggregate formation in the eye lens.

Liquid microparticle formulations transition to solid gels in the eye, eliminating incisions and large needles while sustaining drug release.

PEGylated four helical bundle polypeptides extend in vivo half-life by linking water-soluble polymers, reducing administration frequency.

Mirabegron lowers lysosomal pH in retinal pigment epithelium cells to restore cathepsin D activity.

3,5-seco-4-norcholestane derivatives prevent cell death from necrosis and apoptosis, addressing insufficient cytoprotective effectiveness in current treatments.

An AAV vector carrying a codon-optimized TMC1 transgene restores auditory brainstem response and improves hearing thresholds in genetic hearing loss cases.

A multi-dose nasal spray device delivers phosphodiesterase inhibitors directly to the nasal epithelium.

Identifying Plexin B2 as the angiogenin receptor resolves the unknown mechanism gap while enabling targeted cancer therapies.

A PEGylated adiponectin receptor agonist peptide increases tear volume and stability.

Merges pilocarpine and lipoic acid in a fixed ratio to reduce side effects while treating xerostomia.

A photoactive agent embedded in an intrachoroidal implant accelerates drug release upon laser irradiation.

HT-267 CCK-B receptor agonist targets auditory pathways to alleviate tinnitus, avoiding widespread side effects from NMDA antagonists.

Sequential ion exchange and hydrophobic interaction chromatography remove host cell proteins like procathepsin L from antibody mixtures.

A bicyclic heteroaryl derivative inhibits multiple protein kinases.

Segmented non-polar Iceland moss extract targets TRPA1 receptors to relieve pain, resolving the unpredictability of natural actives.

Intravitreal methotrexate implant prevents proliferative vitreoretinopathy by maintaining local drug concentrations without systemic toxicity.